La cannabis nell’epilessia farmacoresistente in età evolutiva

1048

Neurologia

Ludovica Di Francesco1,2, Alberto Verrotti 3

 

  1. Clinica Pediatrica, Università degli Studi ‘G. d’Annunzio’ Chieti – Pescara, Chieti.
  2. Clinica Pediatrica, Università degli Studi dell’Aquila, L’Aquila.
  3. Clinica Pediatrica, Università degli Studi di Perugia, Perugia.

Il Pediatra, n.1-21, pagg. 52-57

Bibliografia

  1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-1077.
  2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
  3. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. New Eng J Med 2015;373:1048–1058.
  4. Ben-Zeev B. Medical Cannabis for Intractable Epilepsy in Childhood: A Review. Rambam Maimonides Med J 2020;11:e0004.
  5. Williams CM, Stephens GJ. Development of cannabidiol as a treatment for severe childood epilepsies. Br J Pharmacol 2020. Online ahead of print.
  6. Arzimanoglou A, Brandl U, Cross JH, et al. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord 2020;22:1-14.
  7. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015;45:49-52.
  8. Porcari GS, Fu C, Doll ED, et al. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav 2018;80:240-246.
  9. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol 2018;9:759.
  10. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270-8.
  11. Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017;377:699-700.
  12. Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 2018;90:e1204-e1211.
  13. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:1085-1096.
  14. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018;378:1888-1897.
  15. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60:419-428.
  16. Thiele E, Bebin M, Hari Bhathal H, et al. Cannabidiol (CBD) Treatment in Patients with Seizures Associated with Tuberous Sclerosis Complex: A Randomized, Double-blind, Placebo Controlled Phase 3 Trial (GWPCARE6). AES meeting, Baltimore. 2019.
  17. Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131-137.

 

 

 

 

ARTICOLI CORRELATIALTRO DALL'AUTORE